R.E. Edwards
3 Papers
18 Citations
R.E. Edwards is an academic researcher. The author has contributed to research in topics: Antibody & Immunology. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study.
Ghady Haidar,Mounzer E. Agha,Andrew Bilderback,Amy Lukanski,Kelsey Linstrum,R. Troyan,Scott D. Rothenberger,Deborah McMahon,Melissa D Crandall,M. Sobolewksi,P. Nathan Enick,Jana L. Jacobs,Kevin Collins,Cynthia Klamar-Blain,Bernard J.C. Macatangay,Urvi M. Parikh,Amy Heaps,Lindsay Coughenour,Marc Schwartz,Jeff Dueker,Fernanda P. Silveira,Mary E. Keebler,Abhinav Humar,James D. Luketich,Matthew R. Morrell,Joseph M. Pilewski,John F. McDyer,Bhanu P. Pappu,Robert L. Ferris,Stanley M. Marks,J.R. Mahon,Katie Mulvey,Sundaram Hariharan,Glenn Updike,Lorraine Brock,R.E. Edwards,Richard H. Beigi,P. L. Kip,Alan Wells,Tami Minnier,Derek C. Angus,John W. Mellors +41 more
TL;DR: Antibody responses to COVID-19 vaccines were lowest among SOT and anti-CD20 monoclonal recipients, and recipients of vaccines other than mRNA-1273, and among those with intermediate antibody levels, pseudovirus neutralization titers were lower in immunocompromised patients than HCW.
51
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)
Ghady Haidar,Mounzer E. Agha,Andrew Bilderback,Amy Lukanski,Kelsey Linstrum,R. Troyan,Scott D. Rothenberger,Deborah McMahon,Melissa D Crandall,M. Sobolewksi,P. Nathan Enick,Jana L. Jacobs,Kevin Collins,Cynthia Klamar-Blain,Bernard J.C. Macatangay,Urvi M. Parikh,Amy Heaps,Lindsay Coughenour,Marc B Schwartz,Jeff Dueker,Fernanda P. Silveira,Mary E. Keebler,Abhinav Humar,James D. Luketich,Matthew R. Morrell,Joseph M. Pilewski,John F. McDyer,Bhanu P. Pappu,Robert L. Ferris,Stanley M. Marks,J.R. Mahon,Katie Mulvey,Sundaram Hariharan,Glenn Updike,Lorraine Brock,R.E. Edwards,Richard H. Beigi,P. L. Kip,Alan Wells,Tami Minnier,Derek C. Angus,John W. Mellors +41 more
TL;DR: Antibody responses to COVID-19 vaccines were lowest among SOT and anti-CD20 monoclonal recipients, and recipients of vaccines other than mRNA-1273, and among those with intermediate antibody levels, pseudovirus neutralization titers were lower in immunocompromised patients than HCWs.
The risk of alloimmunization to c (Rh4) in R1R1 patients who present with anti‐E
TL;DR: It is suggested that R1R1 (E‐, c‐) patients who present with anti‐E alone receive prophylactic c‐ (Rh: −4) red cell transfusions.
21